Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Poly Medicure Limited is an India-based manufacturer of disposable medical devices, specializing in IV therapy products (catheters, infusion sets, blood collection systems) and in-vitro diagnostics. The company operates manufacturing facilities in India with exports to over 100 countries, competing on cost-effective production and regulatory compliance across multiple geographies including Europe (CE Mark), US (FDA), and emerging markets.
Poly Medicure generates revenue through high-volume manufacturing of single-use medical devices with 66.5% gross margins driven by vertical integration (in-house polymer compounding, mold design), economies of scale in Indian manufacturing, and regulatory moats (FDA, CE Mark certifications create barriers). The company sells through distributors and direct hospital contracts globally, with pricing power derived from quality certifications and switching costs in hospital procurement systems. Operating margins of 46.5% reflect low labor costs in India, automated production lines, and limited R&D requirements for mature product categories.
Export order wins from developed markets (US, Europe) where pricing and margins are 30-40% higher than emerging markets
Capacity utilization rates and commissioning timelines for new manufacturing lines (given $3.3B capex vs $2.4B operating cash flow)
Raw material cost trends for medical-grade polymers (PVC, polyethylene, polypropylene) which represent 20-25% of COGS
Regulatory approvals for new product launches or facility certifications (FDA 510(k), CE Mark expansions)
Currency movements in USD/INR and EUR/INR given significant export exposure
Commoditization pressure in mature IV therapy products as patents expire and Chinese manufacturers scale production with 20-30% lower costs, compressing margins in price-sensitive emerging markets
Regulatory tightening in developed markets (EU MDR, FDA quality system inspections) requiring ongoing compliance investments and potential facility remediation costs
Healthcare cost containment initiatives globally driving group purchasing organization (GPO) pressure for 5-10% annual price reductions on commodity medical devices
Competition from global leaders (BD, B. Braun, Terumo) with broader product portfolios, established hospital relationships, and ability to bundle products for preferred pricing
Chinese manufacturers (Weigao, Shandong Zibo) expanding into regulated markets with FDA/CE approvals and 25-30% cost advantages
Vertical integration by hospital systems and GPOs developing private-label products with contract manufacturers
Negative free cash flow of -$0.9B driven by $3.3B capex creates execution risk if new capacity ramp is delayed or demand assumptions prove optimistic
Currency exposure on USD/EUR-denominated receivables vs INR costs - 10% INR appreciation reduces export margins by 300-400 bps
Inventory obsolescence risk if product certifications lapse or regulatory standards change, requiring write-offs of finished goods
low - Healthcare consumables are non-discretionary with stable demand regardless of GDP growth. Hospital procedure volumes drive consumption, which correlate weakly with economic cycles. However, elective procedures in developed markets can decline during recessions, impacting 10-15% of product mix. Emerging market expansion is more GDP-sensitive as healthcare infrastructure investment accelerates with economic growth.
Rising rates have moderate negative impact through two channels: (1) Higher financing costs for the $3.3B capex program, though 0.08 debt/equity suggests minimal leverage currently; (2) Valuation multiple compression - at 26.7x EV/EBITDA, the stock trades at growth multiples vulnerable to rate-driven re-rating. Lower rates in developed markets also support hospital capital budgets and procurement spending.
Minimal direct credit exposure. Customers are primarily hospitals, government health systems, and large distributors with stable payment profiles. Working capital of 3.89x current ratio indicates strong liquidity. However, tighter credit conditions in emerging markets can delay hospital procurement cycles and extend receivables collection periods from current 60-90 days.
growth - 21.4% revenue growth and 31.1% net income growth attract growth investors despite premium 7.4x P/S and 26.7x EV/EBITDA multiples. The -38.1% one-year return and -31.1% recent drawdown suggest momentum investors have exited, creating potential entry point for fundamental growth buyers focused on 2027-2028 earnings as new capacity ramps. High 46.5% operating margins and 20.3% net margins appeal to quality-focused growth managers.
high - Small-cap healthcare stock with significant export exposure creates volatility from currency swings, regulatory news, and order lumpiness. The -31% three-month decline demonstrates sensitivity to growth concerns or capacity expansion delays. Beta likely 1.3-1.5x relative to Indian healthcare indices given operational leverage and export concentration.
